Generic Name: tivozanib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Aveo Oncology

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Fotivda is a kinase inhibitor approved for the treatment of relapsed or refractory (nonresponsive) advanced renal cell carcinoma, the most common type of kidney cancer.

General Info

Fotivda is a tyrosine kinase inhibitor that blocks the activity of several enzymes, including VEGFR, that play a role in cell growth and development of blood vessels that feed tumors.

The Phase III TIVO-3 trial showed that Fotivda shrank tumors in 18% of patients and delayed disease progression compared with the older kinase inhibitor Nexavar (sorafenib). Fotivda was first approved in 2021.


Dosing Info:

Fotivda is taken as a capsule pill once daily with or without food for 21 days, followed by seven days off, until patients experience disease progression or unacceptable side effects.

Side Effects

Common adverse reactions include fatigue, diarrhea, nausea, loss of appetite, high blood pressure, hypothyroidism, cough, mouth sores and dysphonia (difficulty speaking). Less common but potentially serious side effects include heart problems, blood clots, severe bleeding, protein in the urine, slow wound healing and a brain condition known as reversible posterior leukoencephalopathy syndrome. Fotivda can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: March 29, 2021